home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9410o.zip
/
M94A2827.TXT
< prev
next >
Wrap
Text File
|
1994-10-25
|
3KB
|
41 lines
Document 2827
DOCN M94A2827
TI Binational experience in the treatment of AIDS with a low molecular
weight natural carbohydrate (ECA-10-142), as stimulant of the immunology
system.
DT 9412
AU Cevallos Arellano E; Ardila Ardila H; Oncology Clinic, Metropolitan
Hospital, Quito, Ecuador.
SO Int Conf AIDS. 1994 Aug 7-12;10(1):216 (abstract no. PB0294). Unique
Identifier : AIDSLINE ICA10/94369748
AB OBJECTIVES: to evaluate the stimulant properties of the immunological
system of the (ECA-10-142) a low weight natural origin carbohydrate, in
70 IV CDC stage AIDS patients METHODS: 70 patients with AIDS confirmed
diagnosis were selected, 30 Colombians and 40 Ecuadorians, for oral
treatment with (ECA-10-142). In a period of 9 months. In the evaluations
were considered clinical symptoms and signs, total percentage of
lymphocytes, CD4 and CD8 cells percentage and its relationships. In
vitro studies demonstrated also that this carbohydrate stimulates the
immunological system in the AIDS patients. RESULTS: the obtained results
in the 9 months demonstrated a clinical improvement as to signs and
symptoms in 64 (91.4%) patients, immunological recuperation of CD4
levels in 66 (94.3%) patients, clinical and immunological improvement
were presented in 64 (91.4%) patients, 4 (5.7%) patients died due to
their advanced state of the sickness. They only received treatment
during one month, and had their CD4 levels under 100. DISCUSSION AND
CONCLUSIONS: the (ECA 10-142) has demonstrated to be a useful vitro and
in vivo stimulated of the immunological system as inhibits the formation
of syncytial masses in a 59% and is effective as the clinical and
immunological improvement of AIDS patients. Kinetics studies are
required and observations in a longer time in order to conclude it's
immunostimulating activity in AIDS patients.
DE Acquired Immunodeficiency Syndrome/IMMUNOLOGY/*THERAPY Adjuvants,
Immunologic/PHARMACOLOGY/*THERAPEUTIC USE Biological
Products/*THERAPEUTIC USE Carbohydrates/PHARMACOLOGY/*THERAPEUTIC USE
Colombia Cytopathogenic Effect, Viral/DRUG EFFECTS Ecuador Human
Treatment Outcome CLINICAL TRIAL MEETING ABSTRACT MULTICENTER STUDY
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).